GlassScriptPhysician profile
Cathy Rubel
NPI 1568845782
$6,578.81
in general payments reported to CMS, 2019-2025
20 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $780 · 2022: $1,129 · 2023: $1,403 · 2024: $1,800 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,486 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,486.20 |
| Education | $182.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,588.76 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $734.71 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $633.60 | 2021-2025 | Caplyta |
| Alkermes, INC. | $633.27 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $611.60 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $419.25 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $389.98 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $378.37 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $346.56 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $221.08 | 2021-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $123.03 | 2021-2023 | Andexxa |
| Janssen Pharmaceuticals, INC | $120.57 | 2022-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $119.33 | 2025 | Fanapt |
| Sanofi-Aventis U.S. LLC | $99.19 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $51.51 | 2024-2025 | Cobenfy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $44.62 | 2022 | |
| Harmony Biosciences LLC | $16.23 | 2025 | |
| Corium, LLC | $16.09 | 2022 | |
| Alfasigma USA, INC. | $15.67 | 2021 | |
| Bioxcel Therapeutics, INC. | $15.39 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Rubel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.